- Home
- INVA vs ADNT Comparison
INVA vs ADNT Comparison
Compare INVA & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | ADNT |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | INVA | ADNT |
|---|---|---|
| Price | $21.98 | $19.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 10 |
| Target Price | ★ $36.50 | $24.85 |
| AVG Volume (30 Days) | 641.9K | ★ 716.9K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | $217,217,000.00 | ★ $17,439,000,000.00 |
| Revenue This Year | $8.78 | $2.76 |
| Revenue Next Year | $11.99 | $2.47 |
| P/E Ratio | $6.66 | ★ N/A |
| Revenue Growth | ★ 62.63 | 7.56 |
| 52 Week Low | $16.52 | $10.04 |
| 52 Week High | $25.15 | $27.32 |
Technical Indicators
Market Signals| Indicator | INVA | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 28.00 |
| Support Level | $19.16 | $18.47 |
| Resistance Level | $22.76 | $19.93 |
| Average True Range (ATR) | 0.69 | 0.81 |
| MACD | -0.22 | -0.53 |
| Stochastic Oscillator | 9.47 | 1.94 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.